Compass Therapeutics | Investor Presentation Deck

Slide schematic 3/3

list 2/2 title 1/1

Components 3

bullet bullet headline

Tools 1

list/bullet: 24 patients with BTC have been enrolled and dosed. 9 partial responses (PRs) for a 37.5% ORR in patients treated in the second- and third-line settings (64% ORR of patients treated in the 2nd line setting).

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 1

comparison_frame 90%

Side-by-side presentation of internal clinical data vs external benchmarks.

Find anything

The slide compares internal trial data for CTX-009 against historical benchmarks (FOLFOX and TOPAZ-1) to demonstrate efficacy.